Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025

Rhea-AI Summary

Talphera (Nasdaq: TLPH), a specialty pharmaceutical company, will release its Q2 2025 financial results on Thursday, August 14, 2025 after market close. The company will host a conference call and webcast at 4:30 PM ET/1:30 PM PT to discuss the results and provide a business update.

Investors can access the webcast through Talphera's website investor section, which will include a slide presentation. A replay will be available for 90 days. For those joining by phone, North American callers can dial 1-800-836-8184, while international callers should use 1-646-357-8785 with conference ID 32530.

[]

SAN MATEO, Calif., Aug. 7, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2025 financial results after market close on Thursday, August 14, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business.

Webcast Information

The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event.

Conference Call Information

Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of Canada. The conference ID is 32530.

About Talphera, Inc.

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).

This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-host-second-quarter-financial-results-and-corporate-update-call-and-webcast-on-thursday-august-14-2025-302524765.html

SOURCE Talphera, Inc.

FAQ

When will Talphera (TLPH) report Q2 2025 earnings?

Talphera will release Q2 2025 financial results on Thursday, August 14, 2025 after market close, followed by a conference call at 4:30 PM ET.

How can investors access Talphera's Q2 2025 earnings call?

Investors can join via webcast on Talphera's website or by phone: 1-800-836-8184 (North America) or 1-646-357-8785 (International) using conference ID 32530.

Where can I find Talphera's Q2 2025 earnings presentation slides?

The slide presentation will be available through the webcast and can be accessed in the Investors/News & Events/Upcoming Events section of Talphera's website at www.talphera.com.

How long will Talphera's Q2 2025 earnings call replay be available?

A replay of the webcast will be available on Talphera's website for 90 days following the event.